Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.

Theodoros PapathanasiouAnders StratheHenrik AgersøTrine Meldgaard Lund Rune Viig Overgaard

Published in: Diabetes, obesity & metabolism (2020)

The relationship between liraglutide systemic exposure and weight loss was successfully established in overweight or obese people. The model could predict the time course of weight regain after treatment cessation and suggests that GI tolerability can be mitigated by slower escalation with only minor impact on the weight loss trajectory.

Keyphrases

weight loss
bariatric surgery
gastric bypass
roux en y gastric bypass
open label
glycemic control
weight gain
obese patients
clinical trial
metabolic syndrome
physical activity
body mass index
emergency department
study protocol